Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

References

• Clough KB, Acosta-Marin V, Nos C, et al. Rates of neoadjuvant chemotherapy and oncoplastic surgery for breast cancer surgery: a french national survey. Ann Surg Oncol. 2015;22(11):3504–3511. doi:10.1245/s10434-015-4378-625665949
   PubMed Web of Science ®Google Scholar
• Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544–2552. doi:10.1002/cncr.2934825902916
   PubMed Web of Science ®Google Scholar
• Vugts G, Maaskant-Braat AJ, Nieuwenhuijzen GA, Roumen RM, Luiten EJ, Voogd AC. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. A population-based study. Breast J. 2016;22(3):316–321. doi:10.1111/tbj.1256826945566
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. doi:10.1016/S0140-6736(11)61625-522152853
   PubMed Web of Science ®Google Scholar
• Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685. doi:10.1200/JCO.1998.16.8.26729704717
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi:10.1200/JCO.2007.15.023518258986
   PubMed Web of Science ®Google Scholar
• van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224–4237. doi:10.1200/JCO.2001.19.22.422411709566
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialist' Collaborative Group (EBCTG); Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)30777-529242041
   PubMed Web of Science ®Google Scholar
• Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–194. doi:10.1093/jnci/dji02115687361
   PubMedGoogle Scholar
• Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665–673. doi:10.1056/NEJM1985031431211013883167
   PubMed Web of Science ®Google Scholar
• Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11. doi:10.1056/NEJM1981070230501027015141
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106. doi:10.1016/S0140-6736(05)67887-716360786
   PubMed Web of Science ®Google Scholar
• CC N. Treatment of early breast cancer. JAMA. 1991;265:391–395.1984541
   PubMed Web of Science ®Google Scholar
• Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med. 2009;360(1):63–70. doi:10.1056/NEJMct080352519118305
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. doi:10.5858/arpa.2013-0953-SA24099077
   PubMed Web of Science ®Google Scholar
• Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–1691. doi:10.1200/JCO.2009.24.928420194857
   PubMed Web of Science ®Google Scholar
• Debled M, MacGrogan G, Breton-Callu C, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude. Eur j cancer. 2015;51(6):697–704. doi:10.1016/j.ejca.2015.01.06325704790
   PubMed Web of Science ®Google Scholar
• Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–1665. doi:10.1001/jama.2015.365625919529
   PubMed Web of Science ®Google Scholar
• Sutton AJ, Abrams KR, Jones DR. Methods for Meta-analysis in Medical Research. Wiley Series in Probability and Statistics-applied Probability and Statistics Section. Hoboken: Wiley; 2008.
   Google Scholar
• Ihemelandu CU, Naab TJ, Mezghebe HM, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg. 2008;247(3):463–469. doi:10.1097/SLA.0b013e31815d744a18376191
   PubMed Web of Science ®Google Scholar
• Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010;124(1):187–194. doi:10.1007/s10549-010-1135-120814819
   PubMed Web of Science ®Google Scholar
• Herrero-Vicent C, Guerrero-Zotano A, Gavila-Gregori J, et al. A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. Ecancermedicalscience. 2016;10:647. doi:10.3332/ecancer.2016.64727433280
   PubMedGoogle Scholar
• Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411–2418. doi:10.1245/s10434-010-1008-120373039
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Arunsingh M, Agrawal S, et al. Outcomes following a moderately hypofractionated adjuvant radiation (START B Type) schedule for breast cancer in an unscreened non-caucasian population. Clin Oncol (R Coll Radiol). 2016;28(10):e165–e172. doi:10.1016/j.clon.2016.05.00827369459
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Parinyanitikul N, Lei X, et al. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer. 2015;112(4):630–635. doi:10.1038/bjc.2014.64725584488
   PubMed Web of Science ®Google Scholar
• Palmieri C, Macpherson IR, Yan K, et al. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget. 2016;7(11):13209–13220. doi:10.18632/oncotarget.480126334099
   PubMedGoogle Scholar
• Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. doi:10.1158/0008-5472.CAN-08-177619010901
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–126. doi:10.1016/S1470-2045(17)30716-729175149
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26(4 Suppl 12):60–70.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373–2378. doi:10.1200/JCO.2007.14.428718413639
   PubMed Web of Science ®Google Scholar
• Tsoutsou PG, Vozenin MC, Durham AD, Bourhis J. How could breast cancer molecular features contribute to locoregional treatment decision making? Crit Rev Oncol Hematol. 2017;110:43–48. doi:10.1016/j.critrevonc.2016.12.00628109404
   PubMed Web of Science ®Google Scholar
• Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6(6):e21030. doi:10.1371/journal.pone.002103021695277
   PubMed Web of Science ®Google Scholar
• Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011;128(3):899–906. doi:10.1007/s10549-011-1495-121475999
   PubMed Web of Science ®Google Scholar
• Horton JK, Jagsi R, Woodward WA, Ho A. Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys. 2018;100(1):23–37. doi:10.1016/j.ijrobp.2017.08.02529254776
   PubMed Web of Science ®Google Scholar